SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C. 20549


                                 SCHEDULE 13G
                   Under the Securities Exchange Act of 1934
                               (Amendment No. 3)


                              PHARMANETICS, INC.
--------------------------------------------------------------------------------
                                (Name of Issuer)


                                 COMMON STOCK
--------------------------------------------------------------------------------
                         (Title of Class of Securities)


                                   71713J107
--------------------------------------------------------------------------------
                                 (CUSIP Number)


     Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:

     [_] Rule 13d-1(b)

     [x] Rule 13d-1(c)

     [_] Rule 13d-1(d)


     *The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.

     The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).


CUSIP NO. 71713J107                      13G                        Page 2 of 5
===============================================================================

1.    Name of Reporting Persons/I.R.S. Identification Nos. of Above Persons
      (Entities Only)

                         Joseph H. Sherrill Jr.

------------------------------------------------------------------------------
2.    Check the Appropriate Box if a Member of a Group (See Instructions)
                                                                      (a) [_]
                                                                      (b) [_]

------------------------------------------------------------------------------
3.    SEC Use Only


------------------------------------------------------------------------------
4.    Citizenship or Place of Organization

                                   U.S.

------------------------------------------------------------------------------
                    (5)   SOLE VOTING POWER

     NUMBER OF                552,777

      SHARES       -----------------------------------------------------------
                    (6)   SHARED VOTING POWER
   BENEFICIALLY
                               35,460
     OWNED BY
                   -----------------------------------------------------------
       EACH         (7)   SOLE DISPOSITIVE POWER

    REPORTING                 552,777

      PERSON       -----------------------------------------------------------
                    (8)   SHARED DISPOSITIVE POWER
       WITH
                               35,460
------------------------------------------------------------------------------
9)    Aggregate Amount Beneficially Owned by Each Reporting Person

                                   588,237

------------------------------------------------------------------------------
10)   Check if the Aggregate Amount in Row (9) Excludes Certain Shares
      (See Instructions)                                            [_]

------------------------------------------------------------------------------
11)   Percent of Class Represented by Amount in Row (9)

                                      6.2%

------------------------------------------------------------------------------
12)   Type Of Reporting Person (See Instructions)
                                      IN

------------------------------------------------------------------------------



CUSIP NO. 71713J107                   13G                           Page 3 of 5
===============================================================================
Item 1

     (a) Name of Issuer:

                         PHARMANETICS, INC.

     (b) Address of Issuer's Principal Executive Offices:

                         5301 Departure Drive
                          Raleigh, NC 27616


Item 2

     (a) Name of Person Filing:

                         Joseph H. Sherrill, Jr.

     (b) Address of Principal Business Office or, if none, Residence:

                         1510 Stickney Point Road
                             Sarasota, FL 34231

     (c) Citizenship:

                                   U.S.

     (d) Title of Class of Securities:

                               Common Stock

     (e) CUSIP Number:

                                 7173J107

Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c),
        check whether the person filing is a:

     (a) [_]  Broker or dealer registered under section 15 of the Exchange Act;
     (b) [_]  Bank as defined in section 3(a)(6) of the Exchange Act;
     (c) [_]  Insurance company as defined in section 3(a)(19) of the Exchange
              Act;
     (d) [_]  Investment company registered under section 8 of the Investment
              Company Act;
     (e) [_]  An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
     (f) [_]  An employee benefit plan or endowment fund in accordance with
              Rule 13d-1(b)(1)(ii)(F);
     (g) [_]  A parent holding company or control person in accordance with
              Rule 13d-1(b)(1)(ii)(G);
     (h) [_]  A savings associations as defined in Section 3(b) of the Federal
              Deposit Insurance Act;



CUSIP NO. 71713J107                   13G                           Page 4 of 5
===============================================================================

     (i) [_]  A church plan that is excluded from the definition of an
              investment company under section 3(c)(14) of the Investment
              Company Act;
     (j) [_]  Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

If this statement is filed pursuant to Rule 13d-1(c), check this box. [X]

Item 4. Ownership:

     Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.

     (a)  Amount beneficially owned:    588,237

     (b)  Percent of class:             6.2%

     (c)  Number of shares as to which such person has:

          (i)   sole power to vote or to direct the vote:
                                        552,777

          (ii)  shared power to vote or to direct the vote:
                                        35,460

          (iii) sole power to dispose or to direct the disposition of:
                                        552,777

          (iv)  shared power to dispose or to direct the disposition of:
                                        35,460

Item 5.  Ownership of Five Percent or Less of a Class:
                                   Not applicable

Item 6.  Ownership of More than Five Percent on Behalf of Another Person:
                                   Not applicable

Item 7.  Identification and Classification of the Subsidiary Which Acquired the
         Security Being Reported on by the Parent Holding Company:
                                   Not applicable

Item 8.  Identification and Classification of Members of the Group:
                                   Not applicable

Item 9.  Notice of Dissolution of a Group:
                                   Not applicable

Item 10. Certification:
               By signing below I certify that, to the best of my knowledge and
         belief, the securities referred to above were not acquired and are not
         held for the purpose of or with the effect of changing or influencing
         the control of the issuer of the securities and were not acquired and
         are not held in connection with or as a participant in any transaction
         having that purpose or effect.


CUSIP NO. 71713J107                    13G                          Page 5 of 5
-------------------------------------------------------------------------------

                                   SIGNATURE

     After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.

Dated: January 30, 2002


                                             /s/ Joseph H. Sherrill, Jr.
                                             ----------------------------------
                                             Joseph H. Sherrill, Jr.